We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
-11.51%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$101M
AUM Growth
-$17.5M
Cap. Flow
-$4.67M
Cap. Flow %
-4.63%
Top 10 Hldgs %
44.39%
Holding
99
New
23
Increased
11
Reduced
26
Closed
11

Top Buys

Rank Stock Value
1
ADVM
Adverum Biotechnologies
ADVM
+$1.8M
2
EPIX
ESSA Pharma
EPIX
+$1.59M
3
NEOS
Neos Therapeutics, Inc
NEOS
+$1.4M
4
WINT
Windtree Therapeutics Inc
WINT
+$1.28M
5
ABEO icon
Abeona Therapeutics
ABEO
+$965K

Top Sells

Rank Stock Value
1
CLVS
Clovis Oncology, Inc.
CLVS
+$2.03M
2
EVFM
Evofem Biosciences, Inc. Common Stock
EVFM
+$1.66M
3
ATRC icon
AtriCure
ATRC
+$1.52M
4
DERM
Dermira, Inc.
DERM
+$832K
5
CYNA
CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA)
CYNA
+$812K

Sector Composition

Rank Sector Weight
1 Healthcare 74.78%
2 Financials 0.2%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
APTO
76
DELISTED
Aptose Biosciences, Inc.
APTO
$83K 0.08%
43
-113
-72% -$251K
CRBP icon
77
Corbus Pharmaceuticals
CRBP
$166M
$79K 0.08%
1,667
+447
+37% +$29.8K
ATRS
78
DELISTED
Antares Pharma, Inc.
ATRS
$77K 0.08%
45,000
– –
LKFT
79
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.78B
$70K 0.07%
+1,709
New +$98.5K
ADXS
80
DELISTED
Advaxis Inc
ADXS
$51K 0.05%
+333
New +$80.5K
GLMD icon
81
Galmed Pharmaceuticals
GLMD
$5.13M
$44K 0.04%
+33
New +$54.3K
CHEKW
82
DELISTED
Check-Cap Ltd. Series A Warrant
CHEKW
$28K 0.03%
55,000
– –
AFMD
83
DELISTED
Affimed
AFMD
– –
-2,895
Closed -$390K
LSTA icon
84
Lisata Therapeutics
LSTA
$9.02M
– –
-593
Closed -$166K
ORKA
85
Oruka Therapeutics
ORKA
$5.82B
– –
-376
Closed -$653K
PVLA
86
Palvella Therapeutics
PVLA
$1.99B
– –
-1,563
Closed -$344K
CLVS
87
DELISTED
Clovis Oncology, Inc.
CLVS
– –
-23,090
Closed -$2.03M
SRGA
88
DELISTED
Surgalign Holdings, Inc. Common Stock
SRGA
– –
-2,864
Closed -$555K
EVFM
89
DELISTED
Evofem Biosciences, Inc. Common Stock
EVFM
– –
-2,047
Closed -$1.66M
BITI
90
DELISTED
BIOTIE THERAPIES CORP SPONSORED ADR
BITI
– –
-10,000
Closed -$200K
ECI
91
DELISTED
ENCISION INC
ECI
– –
-1,062,500
Closed -$584K
TTHI
92
DELISTED
TRANSITION THERAPEUTICS INC (CANADA)
TTHI
– –
-59,222
Closed -$124K
1 2 3
4

Similar funds

CDMG
Creek Drive Management Group San Francisco, California $439M AUM
STCG
Speece Thorson Capital Group Minnetonka, Minnesota $439M AUM 10.15% 1-Year Est. Return
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
BOA
Birnam Oak Advisors New York $441M AUM 37.12% 1-Year Est. Return
ECA
Endeavour Capital Advisors Greenwich, Connecticut $441M AUM 21.38% 1-Year Est. Return
WAS
Winch Advisory Services Appleton, Wisconsin $438M AUM 17.59% 1-Year Est. Return

DAFNA Capital Management's Q3 2015 Portfolio in Review

As of Q3 2015, DAFNA Capital Management held 99 positions worth $101M, down 15% from $118M the previous quarter. Its ten largest holdings account for 44% of the portfolio.

DAFNA Capital Management withdrew a net $4.67M in Q3 2015, closing 11 positions and reducing 26 holdings. Its most notable exit was Clovis Oncology, Inc., an estimated $2.03M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 75% of assets, up from 73% a quarter earlier, followed by Financials.

Against the trend, DAFNA Capital Management opened a new position in Adverum Biotechnologies worth $1.16M.

  • DAFNA Capital Management's largest Q3 2015 buy was Adverum Biotechnologies: 14,060 shares worth $1.16M.
  • DAFNA Capital Management added most to Windtree Therapeutics Inc in Q3 2015, an estimated $1.28M increase.
  • DAFNA Capital Management's biggest Q3 2015 reduction was AtriCure, cutting an estimated $1.52M.
  • DAFNA Capital Management fully exited Clovis Oncology, Inc. in Q3 2015, selling an estimated $2.03M.
  • DAFNA Capital Management's ten largest holdings make up 44% of its $101M portfolio in Q3 2015.
  • DAFNA Capital Management opened 23 new positions and closed 11 in Q3 2015.
  • DAFNA Capital Management's portfolio value fell 15% quarter-over-quarter to $101M.

Based on DAFNA Capital Management's 13F filing for Q3 2015, filed 13 Nov 2015.